- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02355145
Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin. (REALITY)
REALITY: A Non-inteRvEntional Study to Observe the rAtionaLe of selectIng add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin in Real-life Practice at 1 Year Distance
Study Overview
Status
Conditions
Detailed Description
A non-interventional, multicenter study to observe the main criteria used in clinical practice by physicians when selecting the second-line add-on therapy in patients with inadequately metformin-controlled type 2 diabetes in 2 time points at 1 year distance. The study will enrol a minimum of 500 patients in each time point, resulting in a total of at least 1000 from approximately 50 investigators from Bulgaria. Each investigator will recruit approximately 10 subjects.
The assignment of the patients to a particular add-on therapy is not decided in advance by the NIS protocol, but falls within current practice and the prescription of medicine is clearly separated from the decision to include the subject in the study. No additional diagnostic and monitoring procedures shall be applied to patients, other than daily clinical practice and the epidemiological methods shall be used for the analysis of collected data. The intention of the study is to collect data on patients with type 2 diabetes and add-on therapies under routine clinical care.
The patients will participate in only one study visit, at the time of enrolment, when they provide the written informed consent, thus allowing the access to their data. Data will be collected by reviewing the medical records of patients.
Two study groups are to be defined at each time-point - one study group enrolled in moment 1 of evaluation (Feb - Mar 2015) and one study group enrolled in moment 2 of evaluation (Feb - Mar 2016). A patient enrolled in study moment 1 may not be enrolled in study moment 2. No patient will be prospectively followed-up during the study.
Investigators participating in this non-interventional study will be diabetologists in outpatient settings, as this group of specialists treats most of the T2DM patients in Bulgaria.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Pleven, Bulgaria
- Research Site
-
Sofia, Bulgaria
- Research Site
-
Stara Zagora, Bulgaria
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Provision of subject informed consent
- Female and/or male aged 18 years and over
- Diagnosis of type 2 diabetes mellitus
- Patients considered inadequately controlled with metformin with a current treatment based on any add-on diabetes therapy
Exclusion Criteria:
- Diagnosis of type 1 diabetes
- Current antidiabetes treatment with oral monotherapy
- Insulin treatment for type 2 diabetes
- Current participation in any clinical trial
- Patient who have been enrolled in the study at point 1 can not be enrolled at point 2
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Patient group in moment 1 of evaluation
Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
|
Patient group in moment 2 of evaluation
Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the frequency of usage by physicians of the main criteria for selecting the add-on therapy in patients with inadequately metformin-controlled type 2 diabetes
Time Frame: From moment 1 (up to 2 months from FSI) to moment 2 (1 year after moment 1)
|
To describe and compare the main criteria used by physicians (regular outpatient setting) in selecting the add-on therapy in patients with inadequately metformin-controlled type 2 diabetes in 2 time points at 1 year distance.
Descriptive analysis will be produced for the response to questions stratified by patients (binominal variable) and within physician clusters (derived percentages).
To describe the overall changes descriptive analysis will be used for those physician who have responses both in 2 time points at 1 year distance.
|
From moment 1 (up to 2 months from FSI) to moment 2 (1 year after moment 1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of years (duration) of add-on therapies in type 2 diabetes
Time Frame: in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
To describe the usage of add-on therapies in type 2 diabets and changes observed in 1 year.
Descriptive analysis will be used within physician cluster for those physicians who have responses both in 2 time points at 1 year distance.
|
in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
Percentage of subjects with specific comorbid conditions and/or diabetes complications
Time Frame: in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
To evaluate the prevalence of comorbidities and diabetes complications in study groups.
Descriptive analysis will be produced within physician cluster.
|
in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
Percentage of patients with target HbA1c level < 7% at the 2 time-points
Time Frame: in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
To evaluate the percentage if patients with target HbA1c level < 7% at the 2 time-points, by assessment of their last available HbA1c value.
Descriptive analysis will be produced within physician cluster.
|
in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
Number of years of type 2 diabetes disease duration
Time Frame: in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
To describe the characteristics of the disease at the time of initiating the add-on therapy in Bulgarian patients with type 2 diabetes.
Descriptive analysis will be produced within physician cluster.
|
in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
Frequency of the used classes of drugs
Time Frame: in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
To describe the usage of add-on therapies in type 2 diabets and changes observed in 1 year.
Descriptive analysis will be used within physician cluster for those physicians who have responses both in 2 time points at 1 year distance.
|
in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
Number of years until starting the add-on therapies after diagnosis
Time Frame: in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
To describe the characteristics of the disease at the time of initiating the add-on therapy in Bulgarian patients with type 2 diabetes.
Descriptive analysis will be produced within physician cluster.
|
in 2 time points at 1 year distance - moment 1 (up to 2 months from FSI) and moment 2 (1 year after moment 1)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Marina Staneva, AstraZeneca Bulgaria
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1843R00243
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China